60 Degrees Pharmaceuticals (NASDAQ:SXTP) Receives Neutral Rating from HC Wainwright

HC Wainwright reaffirmed their neutral rating on shares of 60 Degrees Pharmaceuticals (NASDAQ:SXTPFree Report) in a research note released on Wednesday morning, Benzinga reports.

60 Degrees Pharmaceuticals Stock Performance

SXTP opened at $0.28 on Wednesday. 60 Degrees Pharmaceuticals has a twelve month low of $0.22 and a twelve month high of $8.65. The company has a 50-day moving average price of $0.30 and a 200 day moving average price of $0.61.

Institutional Trading of 60 Degrees Pharmaceuticals

An institutional investor recently bought a new position in 60 Degrees Pharmaceuticals stock. Walleye Capital LLC acquired a new stake in 60 Degrees Pharmaceuticals, Inc. (NASDAQ:SXTPFree Report) in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor acquired 139,304 shares of the company’s stock, valued at approximately $103,000. Walleye Capital LLC owned about 2.40% of 60 Degrees Pharmaceuticals at the end of the most recent quarter. 7.96% of the stock is owned by institutional investors and hedge funds.

60 Degrees Pharmaceuticals Company Profile

(Get Free Report)

60 Degrees Pharmaceuticals, Inc, a specialty pharmaceutical company, engages in the development and commercialization of therapies for the prevention and treatment of infectious diseases in the United States. The company offers Arakoda for malaria preventative treatment. It also engages in the development of Tafenoquine (Arakoda regimen) that is in Phase IIb clinical trial for COVID-19 indications; Tafenoquine, which is in phase IIA clinical trials for babesiosis, fungal pneumonias, and candidiasis disease; and Celgosivir for respiratory viruses and dengue.

Featured Stories

Receive News & Ratings for 60 Degrees Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for 60 Degrees Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.